TREM2 mediates MHCII-associated CD4<sup>+</sup>T cell response against gliomas
ABSTRACT Triggering receptor expressed on myeloid cells 2 (TREM2) was recently highlighted as a novel immune suppressive marker in peripheral tumors. The aim of this study was to characterizeTREM2expression in gliomas and investigate its contribution in glioma progression by usingTrem2-/-mouse line. Our results showed that higherTREM2expression was correlated with poor prognosis in glioma patients. Unexpectedly, TREM2 deficiency did not have a beneficial effect in a pre-clinical model of glioma. The increasedTREM2expression in glioma was likely due to increased myeloid cell infiltration, as evidenced by our single-cell analysis showing that almost all microglia and macrophages in gliomas were TREM2+. Furthermore, we found that deficiency of TREM2 impaired tumor-myeloid phagocytosis and MHCII presentation, and significantly reduced CD4+T cells in tumor hemispheres. Our results revealed a previously unrecognized protective role of tumor-myeloid TREM2 in promoting MHCII-associated CD4+T cell response against gliomas.SUMMARY Authors found that although higherTREM2expression is correlated with poor prognosis in glioma patients, its absence has no beneficial effect in a pre-clinical model of glioma. Deficiency of TREM2 impairs myeloid cell phagocytosis of tumor debris, leading to a reduction in MHCII-dependent CD4+anti-glioma immunity..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
bioRxiv.org - (2024) vom: 23. Apr. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zheng, Jiaying [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| doi: |
10.1101/2023.04.05.535697 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI039189708 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI039189708 | ||
| 003 | DE-627 | ||
| 005 | 20240424104715.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230407s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2023.04.05.535697 |2 doi | |
| 035 | |a (DE-627)XBI039189708 | ||
| 035 | |a (biorXiv)10.1101/2023.04.05.535697 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zheng, Jiaying |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a TREM2 mediates MHCII-associated CD4<sup>+</sup>T cell response against gliomas |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a ABSTRACT Triggering receptor expressed on myeloid cells 2 (TREM2) was recently highlighted as a novel immune suppressive marker in peripheral tumors. The aim of this study was to characterizeTREM2expression in gliomas and investigate its contribution in glioma progression by usingTrem2-/-mouse line. Our results showed that higherTREM2expression was correlated with poor prognosis in glioma patients. Unexpectedly, TREM2 deficiency did not have a beneficial effect in a pre-clinical model of glioma. The increasedTREM2expression in glioma was likely due to increased myeloid cell infiltration, as evidenced by our single-cell analysis showing that almost all microglia and macrophages in gliomas were TREM2+. Furthermore, we found that deficiency of TREM2 impaired tumor-myeloid phagocytosis and MHCII presentation, and significantly reduced CD4+T cells in tumor hemispheres. Our results revealed a previously unrecognized protective role of tumor-myeloid TREM2 in promoting MHCII-associated CD4+T cell response against gliomas.SUMMARY Authors found that although higherTREM2expression is correlated with poor prognosis in glioma patients, its absence has no beneficial effect in a pre-clinical model of glioma. Deficiency of TREM2 impairs myeloid cell phagocytosis of tumor debris, leading to a reduction in MHCII-dependent CD4+anti-glioma immunity. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Wang, Lingxiao |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Shunyi |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Wenjing |e verfasserin |4 aut | |
| 700 | 1 | |a Chang, Yuzhou |e verfasserin |4 aut | |
| 700 | 1 | |a Dheer, Aastha |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Shan |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Shengze |e verfasserin |4 aut | |
| 700 | 1 | |a Ayasoufi, Katayoun |e verfasserin |4 aut | |
| 700 | 1 | |a Al-kharboosh, Rawan |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Manling |e verfasserin |4 aut | |
| 700 | 1 | |a Johnson, Aaron J. |e verfasserin |4 aut | |
| 700 | 1 | |a Dong, Haidong |e verfasserin |4 aut | |
| 700 | 1 | |a Quiñones-Hinojosa, Alfredo |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Long-Jun |e verfasserin |0 (orcid)0000-0001-8019-3380 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2024) vom: 23. Apr. |
| 773 | 1 | 8 | |g year:2024 |g day:23 |g month:04 |
| 856 | 4 | 0 | |u https://doi.org/10.1093/neuonc/noad214 |x 0 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2023.04.05.535697 |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 23 |c 04 | ||